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Abstract: Hepatitis delta virus (HDV) is a defective RNA virus that has an absolute 
requirement for a virus belonging to the hepadnaviridae family like hepatitis B virus (HBV) 
for its replication and formation of new virions. HDV infection is usually associated with a 
worsening of HBV-induced liver pathogenesis, which leads to more frequent cirrhosis, 
increased risk of hepatocellular carcinoma (HCC), and fulminant hepatitis. Importantly, no 
selective therapies are available for HDV infection. The mainstay of treatment for HDV 
infection is pegylated interferon alpha; however, response rates to this therapy are poor. A 
better knowledge of HDV–host cell interaction will help with the identification of novel 
therapeutic targets, which are urgently needed. Animal models like hepadnavirus-infected 
chimpanzees or the eastern woodchuck have been of great value for the characterization of 
HDV chronic infection. Recently, more practical animal models in which to perform a 
deeper study of host virus interactions and to evaluate new therapeutic strategies have been 
developed. Therefore, the main focus of this review is to discuss the current knowledge about 
HDV host interactions obtained from cell culture and animal models. 
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1. Introduction 
1.1. The Disease, Chronic HDV Infection 
Worldwide there are approximately 350 million individuals chronically infected with the hepatitis B 
virus (HBV); among them 15 to 20 million are coinfected with hepatitis delta virus (HDV) [1].  
HDV was first described in 1977 when a novel antigen was detected in the nucleus of hepatocytes from 
patients chronically infected with HBV who developed serious episodes of severe liver disease [2]. In 
1980 the same research group discovered that this nuclear antigen was derived from a new virus that 
they named hepatitis delta virus [3]. Thus, HDV was established as the causative infectious agent 
responsible for exacerbation of liver disease in HBV-infected patients [4,5]. HBV/HDV coinfection is 
associated with more severe acute hepatitis, higher risk of cirrhosis and decompensated liver disease, 
and higher mortality than HBV monoinfection. From 1990, after the initiation of the universal HBV 
vaccination campaigns, the incidence of HBV and concomitantly of HDV declined in the developed 
world. However, during the last 10 years, epidemiological studies revealed a stabilization, and in some 
cases an increase, in the incidence of HDV in several countries [6–11]. Furthermore, the epidemiology 
of HDV has not changed in developing countries where the HBV vaccine is not being administered to 
the population. Thus, HDV chronic infection represents a major health problem worldwide. Unfortunately, 
the treatment options for chronic HDV are limited. The only drug in use is pegylated interferon-α (PEG-IFN-
α), which is associated with a low rate of cure and a significant number of patients in whom the virus 
relapses after cessation of treatment [12–14]. In addition, PEG-IFN-α is associated with a variety of 
adverse events, including flu-like symptoms, neuropsychiatric events, anemia, and thrombocytopenia. 
Thus, more effective treatment options are needed. The particular characteristics of HDV make the 
development of new therapeutic approaches very difficult. HDV depends on the activity of cellular 
enzymes to complete its life cycle and does not code for viral enzymes, which in the case of other viruses 
represent the main targets for the development of specific antivirals. 
New treatments based on the use of interference RNA molecules [15,16] or—peptides to inhibit  
HDV-HBsAg interaction to block viral entry into cells—are being explored [17–21]. Moreover, 
inhibition of enzymatic processes that are required by the virus to complete its life cycle, e.g. the 
prenylation of viral antigens, represents a very interesting target [22,23]. Currently the antiviral activity 
of two prenylation inhibitors is being tested by Eiger BioPharmaceuticals in phase 2 clinical trials; these 
drugs are expected to become the first “specific” treatment for HDV. 
1.2. Main Characteristics of HDV 
HDV is the only member of the genus Deltavirus. HDV is a defective RNA virus that requires the 
HBV surface antigens (HBsAg) for viral assembly and transmission [14,24]. HDV virion is a small and 
spherical hybrid particle with a diameter of about 36–46 nm [24]. It is composed of the HDV RNA 
genome and about 200 molecules of hepatitis delta antigen (HDAg) enclosed by the hepatitis B surface 
antigen (HBsAg) and host lipids membrane (Figure 1). The HBsAg envelope protects the viral genome 
from the extracellular environment and dictates the hepatocyte tropism of HDV. 
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Figure 1. Schematic representation of HDV virions describing all the components of the 
viral particle. L-HDAg: HDV Large antigen; S-HDAg: HDV short antigen; S-HBsAg: Small 
HBV surface antigen; M-HBsAg: Medium HBV surface antigen; L-HBsAg: Large HBV 
surface antigen; ssRNA: single-stranded RNA. 
The HDV genome is a circular negative sense RNA molecule of approximately 1700 nucleotides with 
the ability to fold on itself, appearing as a double-stranded rod-like structure with approximately 70% 
intramolecular base-pairing [25–27]. Its structure and function is very similar to the genome of plant 
viroids. In fact, replication of the HDV genome involves a rolling circle mechanism, requiring 
autocatalytic cleavage of the RNA by an internal ribozyme analogous to that proposed for plant viroids 
[28–30]. HDV genome replication involves only RNA species; in addition to the genome, infected cells 
contain, in smaller amounts, an exact complementary RNA species, called the antigenome, and much 
smaller amounts of a messenger RNA with a 5'-cap and a 3'-poly(A) tail. HDV isolates have been divided 
in eight clades based on nucleotide sequence and geographic distribution. The different isolates can differ 
in more than 30% of their nucleotide sequence [31]. 
1.3. Virus Life Cycle 
To complete a cycle of HDV infection the hepatocyte must be infected by both HDV and HBV, since 
the formation of new viral particles requires HBV surface antigens. HDV infectivity is dependent upon 
a receptor-binding motif in the N-terminal region of the pre-S1 domain of the HBsAg [18,32].  
Very recently, the receptor for both HBV and HDV infection has been identified as the human  
sodium-taurocholate cotransporting polypeptide (hNTCP) [32–34]. The NTCP is a transmembrane transporter 
present on the basolateral membrane of hepatocytes and is responsible for the uptake of conjugate bile acids 
from enterohepatic circulation [35]. After entering the hepatocytes, the virus is uncoated and a signal in 
the HDAg amino acid sequence mediates the traslocation of the nucleocapsid into the nucleus [36]. To 
replicate its genome, the virus uses the host RNA polymerase/s [37]. Once inside the nucleus, cellular 
RNA polymerases synthesize the antigenomic RNA in the nucleolus and genomic RNA in the 
nucleoplasm (Figure 2) [26,37–40]. There is some controversy about which types of cellular RNA 
polymerases are involved in HDV RNA replication. Host RNA polymerases I, II, and III have been 
shown to interact with the HDV genome [41]. However, while RNA polymerase II was consistently 
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found to interact with HDV components; the interaction with RNA polymerases I and III was not that 
clear [42]. 
 
Figure 2. Schematic representation of the HDV viral cycle: (1) Binding to NTCP on human 
hepatocyte; (2) Uncoating; (3) Translocation of the ribonucleoprotein particle into the nucleus; 
(4) Transcription of the antigenome in the nucleolus.; (5) Production of genomic RNA in the 
nucleoplasm; (6) Transcription of the mRNA; (7) Translation of HDAg; (8) 
Ribonucleoparticle assembly; (9) Asotiation of HBsAg Virion production in the cytoplasm; 
(10) Virion release. HBV cccDNA: HBV covalently closed circular DNA. HBV mRNAs: 
HBV messenger RNAs. 
Studies performed by different groups, particularly by Taylor and colleagues, indicated that the replication 
of the RNA genome, antigenome, and messenger RNA of HDV involves RNA polymerase II [43,44]. This 
is mainly substantiated by the sensitivity of HDV RNA replication to the RNA polymerase inhibitor α-
amanitin. However, the role of RNA polymerases I and III is still under consideration. RNA polymerase 
inhibition studies demonstrated de novo synthesis of HDV antigenome RNA molecules in the presence 
of a RNA polymerase II inhibitor, while its synthesis is decreased in the presence of RNA polymerase I 
inhibitor, suggesting that RNA polymerase I might be involved in this process [45]. More studies need 
to be performed to clarify these issues; however, what is clear is that the enzyme mainly involved in this 
HDV replication is RNA polymerase II. 
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HDV RNA is synthesized first as linear concatameric RNA that contains many copies of the  
genome. [28,30]. Then, the 85-nt site-specifc viral ribozyme, found on each RNA strand, acts to process 
the RNA transcripts to unit lengths, monomers. These monomers are then ligated to form circular RNA. 
It is unclear if ligation is carried out by the ribozyme or a host RNA ligase [46]. During HDV replication, 
it is possible to detect three forms of HDV RNA: circular genomic RNA, circular complementary 
antigenomic RNA, and a linear polyadenylated antigenomic RNA, which is the mRNA template 
containing the open reading frame for the translation of the hepatitis delta antigen (HDAg) [47].  
There are two isoforms of the HDAg: the 24 kDa small form (S-HDAg), with 195 amino acid residues, 
and the 27 kDa large form (L-HDAg) with 214 amino acids [47]. The amino acid sequence of both isoforms 
is identical in the N-terminus, but L-HDAg is 19 amino acids longer at the C-terminus than S-HDAg. 
S-HDAg is encoded by the viral genome and L-HDAg is the result of an RNA editing event mediated 
by host enzyme adenosine deaminase-1 (ADAR-1). ADAR-1 replaces the stop codon UAG at position 
196 with a tryptophan codon UGG, extending the open reading frame and leading to the production of 
the large antigen [48–51]. The 19 extra amino acids added at the carboxyl terminal end of L-HDAg 
confer its functional properties that are different from S-HDAg. S-HDAg is required for the initiation of 
the viral genome replication; it is essential for the transcription and accumulation of newly processed 
HDV RNAs, whereas L-HDAg, which is synthesized in the late stage of viral replication, serves as a 
principal inhibitor of replication and is essential in the assembly of HDV virions. L-HDAg, by inhibiting 
viral replication, also regulates its own synthesis since it prevents the editing of the amber/W site 
necessary for the expression of L-HDAg. Furthermore, the HDV genome and antigenome associate with 
multiple copies of the S-HDAg and L-HDAg, forming ribonucleoprotein complexes (RNPs). Only the 
RNPs containing the HDV genomic molecule interact with HBV surface molecules and form new viral 
particles [52]. 
Both antigens suffer posttranslational modifications, which are very important to modulate their 
functions. S-HDAg is acetylated, phosphorylated, and sumoylated and L-HDAg is acetylated, 
phosphorylated, and isoprenylated. S-HDAg phosphorylation is crucial for its interaction with cellular 
RNA polymerase II and RNA binding. Sumoylation of S-HDAg results in an increase in HDV genomic 
RNA and mRNA synthesis. Acetylation of both antigens modulates HDV replication. Acetylation and 
phosphorylation of L-HDAgs are essential for the correct trafficking of this antigen inside the nucleus 
(nucleolus-nuclear speckles) and secretion. Isoprenylation of the L-HDAg is essential for the interaction 
of L-HDAg with HBSAg and the formation of new virions. The exact location where L-HDAg and 
HBsAg antigens interact is not well known; isoprenylated L-HDAg is mainly located in the nucleus and 
HBsAg is in the cytoplasm, thus L-HDAg forming part of HDV RNPs needs to be exported from the 
nucleus to the cytoplasm. The elucidation of the mechanism involved in this step requires more studies.  
HDV viral particle generation depends on HBV surface antigen production; however, it is still not 
clear if HDV infection can persist in the absence of HBV replication. Contradictory data about this issue 
are available in the literature. It has been reported that HDV RNA, when introduced in human cells in 
the absence of HBV, can replicate efficiently, produce HDAgs, and form RNPs that are not able to exit 
the cell. Furthermore, if another alternative source of HBV envelope proteins is available, like integrated 
HBV DNA, HDV can replicate itself independently of hepadnavirus replication [53]. In fact, HCC cells 
that apparently no longer support HBV replication but can still produce the envelope proteins from HBV 
integrants can generate HDV infectious particles [54]. Recent studies performed in mice with humanized 
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livers showed that HDV monoinfection can persist on human hepatocytes for at least 6 weeks and can 
be rescued by HBV superinfection [55]. In addition, data in a very small number of patients showed that 
HDV can survive and synthesize HDAg in the absence of detectable HBV [56], However, on the other 
hand, it has been demonstrated that inhibition of hepadnavirus infection in patients and animal models 
by the use of antiviral medication led to reduction or loss of HDV replication [57,58]. Thus, nowadays 
the consensus is that HDV can persist without HBV but only for a brief period of time. 
2. In Vitro HDV–Host Cell Interaction 
Although a wide range of cultured cell lines can support HDV replication (HEK-293, HeLa, Huh7) 
after the transfection of a plasmid containing the HDV genome, the virus fails to infect any cultured cell 
lines except primary cultures of hepatocytes and Hepa RG cells with a very low efficiency [59]. 
However, very recently this situation has dramatically changed with the discovery of the HBV/HDV 
receptor. Human as well as other species cell lines that stably express the sodium taurocholate receptor 
have been generated; these cells are infected by and are able to sustain HDV replication [32–34]. 
In order to elucidate the mechanism responsible for the increase in liver pathology observed in 
patients infected with HDV, several authors have analyzed the interaction of viral components with cell 
components in vitro or in cell culture. The first experiments performed to identify host factors interacting 
with HDAg were performed using a yeast two-hybrid system [60,61]. From these studies a single protein 
was identified and named as delta antigen interacting protein A or DIPA. DIPA is a cellular protein with 
high homology to HDAg. DIPA overexpression inhibits HDV replication; however, confirmatory 
studies and a deeper analysis about the mechanism are lacking. Later on, different proteomic approaches 
have been performed in a variety of cell lines, identifying several factors that interact with delta antigen 
such as subunits of RNA polymerase II complex, hnRNP proteins, RNA helicases, the histone H1, PML, 
nucleolin, B23, Pol I specific factor SL1, the negative transcription elongation factor DSIF, and PKR 
[42]—all of these factors have been suggested to affect HDV replication, but only in some cases 
experimentally proven. 
Furthermore, it has been shown that the HDV RNAs interact with the polypyrimide tract-binding 
protein-associated splicing factor (PSF), PKR, GAPDH, and ADAR-1 [62–65]. In fact, as previously 
indicated, ADAR-1 has been shown to be responsible for HDV antigenome editing [51]. 
Regarding the potential mechanism of HDV-mediated cytotoxicity, it has been reported that cells 
expressing HDV proteins present multiple cellular signaling pathways modified like enhanced ROS 
production, leading to oxidative stress and activation of several transcription factors such as STAT-3 or 
NF-κB [66] or potentiated TGF-β signal activation [67]. These HDV-mediated cellular modifications 
can promote several disease phenotypes associated with HDV infection like liver fibrosis or cellular 
damage. Moreover, HDV can interfere with the JAK-STAT signal transduction pathway in response to 
IFN-α, impairing the phosphorylation of both STAT1 and STAT2 and leading to inefficient IFN-α 
stimulated gene expression [68], which might explain the relatively low antiviral efficacy of PEG-IFN-α. 
There is also evidence suggesting that both HDAgs are transcriptional inducers, as both are capable 
of regulating cellular gene expression presenting L-HDAg broader transcriptional activity [69–71].  
One mechanism mediating such effects can be histone acetylation, as an upregulation of this 
modification associated with expression of both HDAgs and HDV replication has been observed [72]. 
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Proteomic analysis of cells producing whole HDV RNPs shows a set of changes in host protein 
synthesis that in some cases seems to correlate with previous pathologic findings observed in both 
chronic and acute HDV patients, like changes in enzymes involved in lipid metabolism [63]. Furthermore, 
this study indicates an overall deregulation of DNA replication and cell cycle control in liver cells, like 
downregulation of PCNA and the Fen 1 endonuclease, proteins involved in DNA replication. This 
observation is in accordance with the subtle growth disadvantage associated with HDV replication in 
dividing cells and deregulation of cell cycle control [73,74]. Regarding innate immune responses, there 
are no data in the literature describing molecules implicated in the detection of the virus or pattern 
recognition receptors that detect HDV. However, it has been shown that elements of the virus are able 
to transactivate the IFN-α-inducible MxA gene [66] and to activate PKR [75]. 
3. Chronic HDV Infection Animal Models 
3.1. “Natural” Animal Models 
In a natural setting, only humans are known to acquire HDV infection [24]; however, it is quite 
possible that chimpanzees or other large primates can be infected with HDV in the wild. As previously 
described, the HDV virus requires help from a virus of the family hepadnaviridae for formation of new 
virions, thus the host range of HDV is limited to those species that support the replication of HBV, like 
chimpanzees, or a hepadnavirus capable of supplying helper functions [76–80]. Among members of the 
Hepadnaviridae family, the closest to HBV are the woolly monkey hepatitis B virus (WMHBV) and the 
woodchuck hepatitis virus (WHV), which can assist in HDV propagation because both encode viral 
envelope proteins that are competent for HDV ribonucleoprotein (RNP) envelopment [81]. In contrast, 
the envelope protein of duck hepatitis B virus (DHBV), the most distantly related hepadnavirus, is unable 
to assist in HDV propagation due to the inability of the envelope protein to package HDV RNP [82]. 
Recently, bats have been described as a new animal model that could support HDV replication based on 
the presence of a HBV antigenically related pathogenic hepadnavirus that can generate HDV 
pseudotyped particles able to infect human and bat primary hepatocytes [83]. Based on its close 
phylogenetic relation to primates, the tree shrew species Tupaia belangeri has been used for infection 
studies both with HBV and WMHBV [21,84,85], and is also a host for HDV infection [86]. 
Among these models, the most frequently used for experimental studies is the woodchuck chronically 
infected with WHV and superinfected with HDV, obtaining interesting and relevant data. Experimental 
transmission of HDV has been accomplished in the chimpanzee and the eastern woodchuck, hosts of 
HBV and WHV, respectively [76,87]. In both models upon HDV infection, there is a major suppression 
of HBV and WHV replication at the peak of HDV replication, as has been observed in humans [88]. 
Eighty to one hundred percent of HDV superinfections in WHV carrier woodchucks resulted in chronic 
HDV infection, while coinfection resulted in an acute self-limited infection. 
It has been shown that woodchucks treated with cyclosporine A, as an inhibitor of the immune 
response, showed an increase in HDV viremia and at the same time a reduction of WHV viral load. 
These results indicate that the host immune response exerts a negative control over HDV replication and 
that HDV influences HBV replication independently of the host immune response [89]. Furthermore, 
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this model was used during the last years to test vaccination strategies designed to protect HBV carriers 
from HDV superinfection [90–94]. 
These natural animal models have provided very useful data and they have allowed for determining 
the main characteristics of the HDV infective cycle and some immunological responses as they 
recapitulate several of the biological phenomena observed in humans. However, there are several 
limitations for performing experiments in these animal models that have delayed the HDV research field, 
ranging from the relatively large size and genetic variability of these animals to availability and ethical 
considerations. Furthermore, several issues limit the number of animals that can be used, affecting the 
statistical significance of any potential results. On top of that, the experimental tools available to work with 
most of these animal species are very limited, highlighting the need for the development of more practical 
animal models. 
3.2. Mouse Models of HDV Replication 
3.2.1. Injection of Mice with HDV Infectious Particles 
The mouse represents the premier mammalian model system for disease research. Scientists from a 
wide range of biomedical fields have gravitated to the mouse because of its close genetic and 
physiological similarities to humans, as well as the ease with which its genome can be manipulated and 
analyzed. Additionally, scientists have developed a broad range of technological tools and approaches 
to dissect molecular and physiological processes in one organism that is easy to maintain. Therefore, 
there have been several attempts by scientists aimed at developing mice as an HDV experimental system. 
The first proof of concept study of HDV infection in mice was performed in 1993, by the group of 
Dr. Taylor at the Fox Chase Cancer Center in Philadelphia; they showed that human hepatitis delta virus 
(HDV) obtained from the serum of an experimentally infected woodchuck and injected into either the 
peritoneal cavity or the tail vein of mice was able to infect the murine liver. In this model, genomic HDV 
increased in the liver during the first 5 to 10 days postinoculation; antigenomic RNA was also detected, 
and delta antigen was present in the nuclei of the hepatocytes [44]. The infection was liver-specific but 
involved no more than 0.6% of the mouse hepatocytes. Once HDV entered mouse hepatocytes, the levels 
of HDV genome replication were comparable to those obtained in a natural infection of woodchuck 
hepatocytes; however, the infection was short lived, with a half-life of clearance of about 3 days. 
Moreover, no obvious cytopathic effects were detected. 
The reason for the disappearance of the viral genome from the liver was not determined, but the role 
of T- and B-cell-dependent immune response can be excluded, since the rate of this decrease was the 
same in both normal mice and those with a severe combined immunodeficiency. Unfortunately, there 
are no more reports suggesting HDV infectivity in mice, probably as a consequence of the unproductive 
HBsAg binding to mNTCP receptor, as has been recently described. 
3.2.2. HDV Transgenic Mice 
As previously described, HDV infection clearly increases the severity of liver pathology in patients 
with HBV chronic infection, but the molecular mechanism involved in the exacerbation of liver 
pathology associated with HDV infection is still unknown. Some authors suggest a potential cytophatic 
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effect of this virus according to data obtained in chimpanzees, particularly during an acute infection [95]. 
Work performed by other groups suggested the potential direct pathogenic role of HDV antigens. S-HDAs 
have been shown to have a cytotoxic effect when overexpressed in HepG2 or HeLa cells, inducing the 
necrosis of the cells [96]. Additionally, it has been postulated that the L-HDAg might play a role in HDV 
pathogenesis due to its capacity to activate many eukaryotic promoters and modulate different signaling 
pathways [62,73,74]. In order to elucidate the role of HDV antigens in the exacerbation of liver disease, 
the group of Dr. Frank Chisari at Scripps, La Jolla, CA, developed transgenic mice for expression of S-
HDAg or L-HDAg in the liver [97]. These animals express HDAgs in hepatocyte nuclei, as observed in 
natural HDV infection. However, no obvious signs of biological or histopathological evidence of liver 
disease, cytotoxicity, or hepatitis were detectable during the mice’s lifespan. Furthermore serum 
transaminase levels remained within the normal range, indicating that neither the large nor small form 
of HDAg are directly cytopathic to the hepatocyte in vivo [97]. Thus, contrary to expectations, HDAg in 
vivo does not seem have a pathological role. 
Because HDV infection occurs mainly in the context of a coexisting HBV infection, the authors asked 
if the liver damage observed in patients with HDV infection might require the presence of both HDAgs 
and HBsAgs. To answer this question, the authors crossed HDAg transgenic mice with HBsAg 
transgenic mice. Once again no histopathological or biochemical evidence of liver cell injury was 
observed, indicating that viral proteins are not directly cytopathic to the hepatocyte. The authors suggest 
that maybe the presence of other HBV proteins is required to promote hepatocyte damage [97]. However, 
the role of the immune response against viral antigens should not be forgotten. Transgenic animals’ 
HDAg is expressed at fetal stages since the transgene is driven by an albumin promoter and the animals 
will recognize the viral antigen as a self-antigen, inducing a tolerogenic immune response. Moreover, 
liver injury associated with HDV infection could be a consequence of HDV and HBV protein and viral 
replication presence or the response of the host to the same factors. 
After the transgenic animal model expressing HDAgs, a new transgenic mouse carrying a  
replication-competent HDV genomic dimer RNA was developed (HDVTg). HDVTg mice have been 
shown competent for studying HDV replication in vivo [98]. Surprisingly, despite the expression of HDV 
being under the control of the albumin promoter, HDV genomic and antigenomic sequences were 
detected in the liver, brain, testis, kidney, and particularly in skeletal muscle, where the amount of HDV 
RNA was 100-fold higher than in the liver. These results indicate that the transcriptional leakage 
associated with the albumin promoter allows HDV priming expression and consequently licenses HDV 
replication in several tissues. The presence of antigenomic HDV monomer RNA is possible only after 
processing and replication of the primary genomic dimer transcript; thus, the data in this transgenic 
animal model indicated that HDV can replicate in nearly all cell types. Interestingly, it is observed that 
HDV replicates more efficiently in muscle cells than in the hepatocytes, indicating that the hepatic 
specificity of HDV is due to the HBV-derived envelope. Moreover, analysis of HDV antigen expression 
showed a similar pattern, i.e., HDV small antigen was detected mainly in the muscles, and in lower 
amounts in the liver. However, no large HDV antigen was detected in any tissue, indicating that no 
efficient HDV RNA editing occurs in these animals. Finally, and in accordance with the results observed 
in HDAg transgenic animals, no evidence of pathology was seen in muscle, brain, or liver tissue without 
any manifestation of necrosis or inflammation. These data indicate that HDV RNA replication and delta 
small antigen expression did not appear to cause any evident pathology and consequently HBVpresence 
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might be required to induce hepatocyte damage. Unfortunately, there is no information about the 
potential immune response against viral antigens in transgenic animals that could help to understand the 
absence of liver damage and could determine if these animals could have any potential for analyzing 
HDV immune responses. 
Although the NTCP gene is highly conserved between species, mouse NTCP does not contain 
molecular determinants required for viral entry [33]. Recent studies have shown that exogenous hNTCP 
expression in a mouse hepatoma cell line allows them to support HDV infection, but not HBV infection. 
Remarkably, in vitro HDV infection was also achieved in cell lines originated from other species and 
tissues expressing exogenous hNTCP, confirming that HDV human hepatotropism is restricted by the 
presence of the hNTCP receptor [32,33]. Therefore, generation of transgenic animals expressing hNTCP 
or a chimeric mNTCP replaced with hNTCP 84 to 87 residues in mouse hepatocytes would be potentially 
susceptible to natural HDV infection. However, these animals would not be susceptible to HBV infection 
as mouse hepatocytes have been shown refractory to HBV infection and they will not support the 
complete HDV life cycle. 
3.2.3. Mice with “Humanized” Livers 
Another approach to study HDV virus replication requires the use of immunodeficient mice with 
human hepatocytes engrafted in their livers [20,55]. To generate mice with humanized livers, the 
investigators induced murine hepatocyte damage to create the space and the environment for engraftment 
and proliferation of human transplanted cells. The first model is based on the use of immunodeficient 
mice transgenic for the urokinase plasminogen activator (uPA-SCID), and the second model is based on 
Rag2-deficient mice and γ chain of interleukin 2 receptor (Il2rg) and lacking the the fumaryl acetoacetate 
hydrolase (Fah) gene. In both cases the animals suffer dramatic hepatocellular damage (death of a high 
percentage of mouse hepatocytes) and mice are rescued by transplantation of human hepatocytes [99]. 
The human cells residing in the mouse liver can proliferate and repopulate host liver tissue and they are 
susceptible to the establishment and maintenance of intrahepatic HDV mono-infection, increasing 
intrahepatic amounts of large HDAg; edited HDV RNA forms increased over time. Moreover, HBV 
superinfection of chimeric mice supporting HDV infection leads to the production of infective HDV 
virion in mice sera and an increase of HDAg-positive human hepatocytes, demonstrating intrahepatic 
HDV spreading [55]. Additionally, HDV infection reduces significantly the increase of HBV viremia 
and intrahepatic cccDNA loads in comparison with HBV mono-infected mice, as has been observed in 
patients. These mice have been used to show the ability of the NTCP inhibitor Myrcludex B to block 
HBV and HDV entry [20]. However, humanized mouse livers present several limitations: 
1. The availability of primary human hepatocytes is limited and they cannot be propagated in vitro, 
which limits the number of available animals. 
2. The susceptibility of primary human hepatocytes to HBV infection is highly variable and generally 
low, since these cells rapidly dedifferentiate, losing the expression of the NTCP receptor. 
3. The engraftment of human hepatocytes in the liver of mice requires the use of immunodeficient 
mice, thus the interaction of the immune system and the virus is lost and consequently 
experiments are restricted to studies analyzing virus host–cell interactions. 
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3.2.4. Development of Gene Delivery Vectors to Deliver HDV Genomes into Mice 
In vivo gene delivery has been widely used for elucidating gene function and for creating disease 
animal models. It is usually performed by a non-viral or viral approach. The former approach mainly 
depends on the use of recombinant DNA or RNA, whereas the latter approach depends on the use of 
viral vectors. The nonviral delivery has several advantages such as less toxicity, less immunogenicity, 
and safer and easier to prepare. However, this approach has limited gene delivery efficiency and results 
in a short duration of transgene expression. 
It has been observed that cloned plant viroids’ cDNA copies are infectious when they are introduced 
in host cells [100]. Similarly, although HDV replication proceeds without DNA intermediates, 
multimeric forms of HDV cDNA transcribed or introduced in the cells are able to initiate the normal 
HDV replication pathway [101,102]. Accordingly, when an HBV-infected chimpanzee was inoculated 
by direct injection into the liver with a recombinant plasmid containing a full-length HDV genome and 
one expression vector allowing the translation of HDAg, it resulted in a productive infection with 
appearance of high levels of HDV RNA and long and short HDVAgs in the liver [103]. HDV RNA and 
HDAg were also detected in serum following a similar kinetic to the one observed in an acute infection, 
generating virions with mature HDV particles characteristics and a marked transient suppression of the 
synthesis of HBV DNA replicative intermediates during the active phase of HDV, as is observed in HDV 
superinfection in both humans and chimpanzees [104,105]. These results suggest that transduction of 
animals with HDV expression vectors can recapitulate most of the HDV viral cycle. 
As previously described, HDV transgenic animals have shown that viral replication in vivo is not 
restricted to the liver and is highly efficient in muscle cells [98]. Consequently, when cDNA dimers of 
HDV were inoculated intramuscularly into mice, HDV genomic RNA increased to substantial levels by 
week 7 post-injection; also, antigenomic sense HDV RNA and hepatitis delta antigen were present in 
myocytes’ nuclei, confirming HDV ubiquitous replication competence, as has been observed in 
transgenic animals. Interestingly, sera from DNA injected mice contained antibodies specific for HDAg, 
indicating the induction of an immunological response to the intracellularly expressed antigen, similar 
to the one observed when mice are inoculated with an HDAg expression vector [106]. When HDV cDNA 
expression vector is hydrodynamically injected in the liver (a technique that allows the transduction of 
10–30% of hepatocytes) there is an increase of genomic and antigenomic HDV RNA for two weeks, 
indicating the existence of HDV RNA replication [107]. Thereafter there is a decrease in HDV genomic 
RNA from day 15 to 30, in clear contrast to what is observed when the vector is inoculated intramuscularly. 
These differences can be caused by the use of different promoters for initial HDV RNA transcription or 
by the stronger HDV replication in muscle in comparison to hepatocytes, as has been previously 
observed in transgenic mice. However, we cannot exclude the possibility that this can also be due to the 
differences in the mouse strain used in each experiment. A similar situation was previously described 
for HBV replication: C57BL/6 mice develop robust HBV replication after hydrodynamic injection of 
HBV plasmids, whereas HBV replication is transient in BALB/c mice [108]. Interestingly, shortly after 
HDV hydrodynamic injection, small HDAg is highly expressed and is detected in nuclei and cytoplasm. 
S-HDAg expression becomes undetectable 15 days after DNA inoculation, indicating that HDAg decline 
precedes HDV RNA reduction. In this animal model, posttranscriptional RNA editing occurs, leading to 
the appearance of the large form of the large delta of HDV. However, L-HDAg protein represents just 
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3% of the accumulated delta protein in the hepatocytes, lower than the levels detected in transfected cells 
and indicating a deficient editing that can promote a suboptimal replication of the HDV genome, which 
results in the disappearance of the HDV genome and antigens. Therefore, it should be clarified whether 
transient HDV replication observed in mouse livers after the HDV-replicative vector is hydrodynamically 
delivered is due to the mouse strain used for the experiments or to liver characteristics. 
As we already indicate several times, the HDV virions require for their formation the hepatitis B virus 
surface antigen subunits provided by HBV co-infection or by the administration of an HBsAg-expressing 
vector. When HBV transgenic mice that produce HBV virions are used as hosts for hydrodynamic 
injection of HDV cDNA, HDV viral particles are detected in the serum [23]. In these mice, HDV 
replicates in hepatocytes and close to 30% of hepatocytes display a characteristic nuclear staining 
observed in HDV-infected cells. There is a good correlation between the level of intrahepatic replication 
and HDV virions’ RNA in the serum. However, as was observed in wild-type animals, HDV replication 
in hepatocytes that contain HBV-replicating virus do not promote an increase in ALT level, as is 
observed in humans and chimpanzees. Moreover, no anti-HDV antibodies were detected in the serum of 
these animals, which might be a consequence of the tolerogenic environment present in HBV transgenic 
mice livers. Very importantly, the majority of the HDV RNA was cleared by day 21 from the livers and 
serum. These animals were useful to demonstrate that pharmacologic prenylation inhibition can prevent 
the production of HDV virions in vivo [23]. 
Taking all these studies together, we can conclude that none of the murine models developed so far 
recapitulate all the features of chronic HDV infection. 
In the last years several groups have developed HBV animal models using a recombinant virus 
carrying the HBV genome, like adenovirus (Ad) [109,110] or adenoassociated virus (AAV) [111,112], 
which acts as a shuttle vector for the delivery of the viral genome into the cells. In our laboratory we are 
currently working on the development of a similar strategy to create a model of HDV chronic infection; 
preliminary data indicates that by using this strategy, persistent HDV replication can be achieved in mice. 
4. Conclusions 
In conclusion, animal models are essential for the knowledge of HDV–host interactions as well as for 
the development of new therapeutic strategies (summarized in Table 1). Data obtained in cell culture are 
in clear contradiction with the data obtained in animal models. While overexpression of HDAgs in cells 
is associated with cytotoxicity, necrosis, and apoptosis, none of these effects are detected in transgenic 
animal models. In this review we showed that the animal models available nowadays that recapitulate 
HDV chronic infection are natural hosts susceptible to infection by members of the hepadnaviridae 
family that can be co-infected with human HDV. However, these animals present obvious ethical and 
experimental limitations. Murine models developed so far do not recapitulate all the characteristics of 
HDV infection, such as RNA editing, sustained viral load, or liver injury. Furthermore, several of them 
were developed in the context of immunosuppressed animals, precluding studies regarding the immune 
response against the virus. This review highlights the need for the development of new small animal 
models that better reflect the main feature of HDV chronic infection and that will allow a deeper analysis 
of HDV–host interaction as well as facilitate the development of new therapeutic agents and/or vaccines. 
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Table 1. Summary of the main characteristics of HDV animal models. 
 Animal model Main characteristics References 
Natural animal 
model  
chimpanzees 
Chimpanzees can be efficiently infected by HDV, coinfection 
and superinfection experiments have been performed resulting 
in moderately severe and severe liver damage, respectively. 
79–81 
 woodchucks 
Several laboratories have shown that woodchucks chronically 
infected with WHV can be infected by HDV and produce new 
HDV virions using WHV surface antigen to form the 
envelope. This animal model recapitulate many of the 
characterists of HDV infection in humans. 
76–78 
 bats 
HDV pseudotyped with surface proteins of bat hepadnavirus 
TBHBV is able to infect both primary hepatocytes, a pattern 
similar to the pattern observed with HDV-HBV 
83 
WT mice 
wild-type & 
inmunodeficient mice 
Mice injected with HDV virus obtained from woodchucks 
transiently infect and replicate in the liver 
44 
HDV-
transgenic 
mice 
S-HDAg transgenic 
mice 
S-HDAg is expressed in hepatocytes and localized in the 
nucleus. No liver injury was observed, thus S-HDAg protein is 
not responsible for HDV inducing liver damage. 
97 
 
L-HDAg transgenic 
mice 
L-HDAg is expressed in hepatocytes an localized in the 
nucleus. No liver injury was observed, thus L-HDAg protein is 
not responsible for HDV inducing liver damage. 
97 
 HDV Ag x HBV sAg 
The phenotype of these mice does not differ from the 
phenotype of the parents 
97 
 
HDV genome under 
the control of the 
Albumin promoter 
HDV replication and S-HDAg expression was detected in 
several organs including the liver, muscle, and brain. However, 
no large HDV large antigen were detected in any tissue, 
indicating that there was no efficient HDV RNA editing. 
Furthermore, no liver pathology was observed. 
98 
Humanized 
mouse models 
Fah-/-RAG-/-IL-2Rg-
/- + human 
hepatocytes 
Establishment of HDV infection was highly efficient in both 
HBV-infected and naïve chimeric mice, representing an 
interesting animal model to study HDV-human hepatocyte 
interaction and new antivirals. 
20,55,99 
HDV-
transfected 
mice 
HDV plasmid 
hydrodynamic 
injection 
In this animal model there is an increase of HDV genome and 
antigenome in the liver but only during the first two weeks 
after hydrodinamic injetion. There is no associated damage. 
Edition is observed in the liver. 
107 
HDV-
transfected 
mice 
HDV plasmid 
intramuscular injection 
Sustained RNA accumulation at least for 7 weeks. HDAg 
antibody generation 
106 
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